AGEN240621C19000
- 0.05
- 0.000.00%
Agenus Newsroom
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%. The iShares Biotechnology ETF (IBB)
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $40 price target.
Agenus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 177.39% HC Wainwright & Co. $40 → $40 Reiterates Buy → Buy 05/24/2024 177.39% HC Wainwright & C
Agenus Shares Rise 12% After Positive Data From Botensilimab/Balstilimab Study
By Chris Wack Agenus shares were up 12% to $15.86 after the company said it saw positive results from an investigator-sponsored trial of botensilimab and balstilimab in the neoadjuvant setting for co
Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients
Agenus (AGEN) shares were up more than 6% in recent Friday trading after the company posted results from an investigator-sponsored trial of botensilimab and balstilimab in the neoadjuvant setting for
Agenus Announces Extended BOT/BAL Therapy Yields Pronounced Tumor Reductions In Colon Cancer; Results From Investigator-Sponsored Trial Presented At 2024 ESMO Gastrointestinal Cancers Congress
Agenus Announces Extended BOT/BAL Therapy Yields Pronounced Tumor Reductions In Colon Cancer; Results From Investigator-Sponsored Trial Presented At 2024 ESMO Gastrointestinal Cancers Congress
Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters
Express News | Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Global LAG-3 Inhibitors Market, Drug Sales & Clinical Trials Market Report: Featuring Abeome, ABL Bio, Agenus, Akeso Biopharma, AnaptysBio, EpimAb Biotherapeutics, Immutep, Incyte and Y-Biologics
Agenus: Buell's Appointment Effective Immediately >AGEN
Agenus: Buell's Appointment Effective Immediately >AGEN
Agenus Appoints Jennifer Buell Chairman of Executive Council >AGEN
Agenus Appoints Jennifer Buell Chairman of Executive Council >AGEN
Express News | Agenus Announces Appointment of DR. Jennifer Buell to Its Board of Directors
Nature Medicine Reports Agenus' Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
BOT/BAL Combination Shows Promising Results in the Most Prevalent Form of Colorectal Cancer, Affecting 95% of Diagnosed Patients Agenus has published results from a groundbreaking clinical trial in Nature Medicine,
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersENDRA Life Sciences (NASDAQ:NDRA) stock increased by 71.6% to $0.15 during Wednesday's pre-market session. The company's market cap stands at $1.5 million. Concord Medical Services (NYSE:CCM) s
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results.Core & Main posted quarterly earnings of 49 cents per share,
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday.Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today's pre-market trading session after the company reported
Agenus Announces Virtual Annual Shareholders Meeting
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a
Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results